- Home
- LNZA vs FGEN Comparison
LNZA vs FGEN Comparison
Compare LNZA & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LNZA | FGEN |
|---|---|---|
| Founded | 2005 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.6M | 35.6M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | LNZA | FGEN |
|---|---|---|
| Price | $13.09 | $8.55 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $14.00 | ★ $146.50 |
| AVG Volume (30 Days) | 8.3K | ★ 39.5K |
| Earning Date | 11-19-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 53.38 |
| Revenue | ★ $39,876,000.00 | $8,298,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $113.27 | N/A |
| P/E Ratio | ★ N/A | $0.17 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.20 | $4.85 |
| 52 Week High | $274.00 | $21.94 |
Technical Indicators
Market Signals| Indicator | LNZA | FGEN |
|---|---|---|
| Relative Strength Index (RSI) | 37.34 | 48.67 |
| Support Level | $13.05 | $8.30 |
| Resistance Level | $14.36 | $10.47 |
| Average True Range (ATR) | 1.06 | 0.61 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 6.53 | 22.58 |
Price Performance
Historical ComparisonAbout LNZA LanzaTech Global Inc.
LanzaTech Global Inc is a carbon management company transforming waste carbon into sustainable fuels, fabrics, packaging, and nutrition. Its goal is to advance a circular economy where carbon is reused rather than wasted, reducing reliance on virgin fossil resources and supporting supply chain resilience. The company operates in North America, Europe, Middle East, Africa (EMEA), Asia, and Australia.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.